IFNB1 and myeloid sarcoma: However, recent studies with DMTs including Beta interferon, Ocrelizumab and Rituximab have suggested that primary progressive MS may respond to immunomodulation highlighting that inflammation plays an important part in progressive phase of the disease [56–58].